Hormone replacement and contraceptive therapy in autoimmune diseases

Aisha Lateef, Michelle Petri

Research output: Contribution to journalArticle

Abstract

Sex hormones, including estrogens, influence the immune system in a complex manner, playing an important role in the pathophysiology of autoimmune diseases. Estrogen receptors can be found in almost all cells, including those of the adaptive and innate immune systems. Depending on the relative preponderance and stimulation of different receptors in various tissues, estrogens may demonstrate pro-inflammatory or anti-inflammatory properties. Traditionally, exogenous estrogens were considered to have the potential of worsening the autoimmune processes and hence were avoided in patients with rheumatic diseases. Recent studies have demonstrated the efficacy of exogenous hormone therapies, either in the form of oral contraceptives or post-menopausal hormonal replacement therapy, in the majority of patients with rheumatic diseases. However, caution needs to be exercised as a higher incidence of mild to moderate flares of systemic lupus erythematosus was noted with hormonal replacement therapy in the large randomized controlled trial, HRT-SELENA. Exogenous estrogens can also increase the risk of thrombosis in patients with positive antiphospholipid antibodies and should be avoided in this subgroup. This review will discuss the current evidence on the efficacy, safety and impact of exogenous sex hormone therapies in patients with autoimmune rheumatic diseases.

Original languageEnglish (US)
JournalJournal of Autoimmunity
Volume38
Issue number2-3
DOIs
StatePublished - May 2012

Fingerprint

Hormone Replacement Therapy
Contraceptive Agents
Autoimmune Diseases
Estrogens
Rheumatic Diseases
Gonadal Steroid Hormones
Immune System
Antiphospholipid Antibodies
Therapeutics
Oral Contraceptives
Estrogen Receptors
Systemic Lupus Erythematosus
Thrombosis
Anti-Inflammatory Agents
Randomized Controlled Trials
Hormones
Safety
Incidence

Keywords

  • Autoimmune diseases
  • Contraception
  • Estrogens
  • Hormone replacement therapy
  • Rheumatoid arthritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Hormone replacement and contraceptive therapy in autoimmune diseases. / Lateef, Aisha; Petri, Michelle.

In: Journal of Autoimmunity, Vol. 38, No. 2-3, 05.2012.

Research output: Contribution to journalArticle

@article{7ed46c23210542789d8b33bfc10e2b94,
title = "Hormone replacement and contraceptive therapy in autoimmune diseases",
abstract = "Sex hormones, including estrogens, influence the immune system in a complex manner, playing an important role in the pathophysiology of autoimmune diseases. Estrogen receptors can be found in almost all cells, including those of the adaptive and innate immune systems. Depending on the relative preponderance and stimulation of different receptors in various tissues, estrogens may demonstrate pro-inflammatory or anti-inflammatory properties. Traditionally, exogenous estrogens were considered to have the potential of worsening the autoimmune processes and hence were avoided in patients with rheumatic diseases. Recent studies have demonstrated the efficacy of exogenous hormone therapies, either in the form of oral contraceptives or post-menopausal hormonal replacement therapy, in the majority of patients with rheumatic diseases. However, caution needs to be exercised as a higher incidence of mild to moderate flares of systemic lupus erythematosus was noted with hormonal replacement therapy in the large randomized controlled trial, HRT-SELENA. Exogenous estrogens can also increase the risk of thrombosis in patients with positive antiphospholipid antibodies and should be avoided in this subgroup. This review will discuss the current evidence on the efficacy, safety and impact of exogenous sex hormone therapies in patients with autoimmune rheumatic diseases.",
keywords = "Autoimmune diseases, Contraception, Estrogens, Hormone replacement therapy, Rheumatoid arthritis, Systemic lupus erythematosus",
author = "Aisha Lateef and Michelle Petri",
year = "2012",
month = "5",
doi = "10.1016/j.jaut.2011.11.002",
language = "English (US)",
volume = "38",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "2-3",

}

TY - JOUR

T1 - Hormone replacement and contraceptive therapy in autoimmune diseases

AU - Lateef, Aisha

AU - Petri, Michelle

PY - 2012/5

Y1 - 2012/5

N2 - Sex hormones, including estrogens, influence the immune system in a complex manner, playing an important role in the pathophysiology of autoimmune diseases. Estrogen receptors can be found in almost all cells, including those of the adaptive and innate immune systems. Depending on the relative preponderance and stimulation of different receptors in various tissues, estrogens may demonstrate pro-inflammatory or anti-inflammatory properties. Traditionally, exogenous estrogens were considered to have the potential of worsening the autoimmune processes and hence were avoided in patients with rheumatic diseases. Recent studies have demonstrated the efficacy of exogenous hormone therapies, either in the form of oral contraceptives or post-menopausal hormonal replacement therapy, in the majority of patients with rheumatic diseases. However, caution needs to be exercised as a higher incidence of mild to moderate flares of systemic lupus erythematosus was noted with hormonal replacement therapy in the large randomized controlled trial, HRT-SELENA. Exogenous estrogens can also increase the risk of thrombosis in patients with positive antiphospholipid antibodies and should be avoided in this subgroup. This review will discuss the current evidence on the efficacy, safety and impact of exogenous sex hormone therapies in patients with autoimmune rheumatic diseases.

AB - Sex hormones, including estrogens, influence the immune system in a complex manner, playing an important role in the pathophysiology of autoimmune diseases. Estrogen receptors can be found in almost all cells, including those of the adaptive and innate immune systems. Depending on the relative preponderance and stimulation of different receptors in various tissues, estrogens may demonstrate pro-inflammatory or anti-inflammatory properties. Traditionally, exogenous estrogens were considered to have the potential of worsening the autoimmune processes and hence were avoided in patients with rheumatic diseases. Recent studies have demonstrated the efficacy of exogenous hormone therapies, either in the form of oral contraceptives or post-menopausal hormonal replacement therapy, in the majority of patients with rheumatic diseases. However, caution needs to be exercised as a higher incidence of mild to moderate flares of systemic lupus erythematosus was noted with hormonal replacement therapy in the large randomized controlled trial, HRT-SELENA. Exogenous estrogens can also increase the risk of thrombosis in patients with positive antiphospholipid antibodies and should be avoided in this subgroup. This review will discuss the current evidence on the efficacy, safety and impact of exogenous sex hormone therapies in patients with autoimmune rheumatic diseases.

KW - Autoimmune diseases

KW - Contraception

KW - Estrogens

KW - Hormone replacement therapy

KW - Rheumatoid arthritis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84858753504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858753504&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2011.11.002

DO - 10.1016/j.jaut.2011.11.002

M3 - Article

VL - 38

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 2-3

ER -